U.S. Plasmid DNA Manufacturing Market (2025 - 2033) Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Segment Definitions
                        1.2.1. Grade
                        1.2.2. Development Phase
                        1.2.3. Application
                        1.2.4. Disease
                    1.3. Information analysis
                    1.4. Market formulation & data visualization
                    1.5. Data validation & publishing
                    1.6. Information Procurement
                        1.6.1. Primary Research
                    1.7. Information or Data Analysis
                    1.8. Market Formulation & Validation
                    1.9. Market Model
                        1.9.1. Objectives
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Trends and Outlook
                    3.3. Market Dynamics
                        3.3.1. Increasing number of patients opting for gene therapy
                        3.3.2. Robust pipeline for gene therapies
                        3.3.3. Highly competitive market and various strategies undertaken by market players
                        3.3.4. Increasing demand for plasmid DNA in various medical therapies
                    3.4. Market Restraint Analysis
                        3.4.1. Regulatory, scientific, and ethical challenges associated with gene therapy
                    3.5. Business Environment Analysis
                        3.5.1. PESTEL Analysis
                        3.5.2. Porter’s Five Forces Analysis
Chapter 4. Grade Business Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
                    4.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
                    4.4. R&D Grade
                        4.4.1. R&D Grade Market, 2021 - 2033 (USD Million)
                        4.4.2. Viral Vector Development
                            4.4.2.1. Viral Vector Development Market, 2021 - 2033 (USD Million)
                            4.4.2.2. AAV
                                4.4.2.2.1. AAV Market, 2021 - 2033 (USD Million)
                            4.4.2.3. Lentivirus
                                4.4.2.3.1. Lentivirus Market, 2021 - 2033 (USD Million)
                            4.4.2.4. Adenovirus
                                4.4.2.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
                            4.4.2.5. Retrovirus
                                4.4.2.5.1. Retrovirus Market, 2021 - 2033 (USD Million)
                            4.4.2.6. Others
                                4.4.2.6.1. Others Market, 2021 - 2033 (USD Million)
                        4.4.3. mRNA Development
                            4.4.3.1. mRNA Development Market, 2021 - 2033 (USD Million)
                        4.4.4. Antibody Development
                            4.4.4.1. Antibody Development Market, 2021 - 2033 (USD Million)
                        4.4.5. DNA Vaccine Development
                            4.4.5.1. DNA Vaccine Development Market, 2021 - 2033 (USD Million)
                        4.4.6. Others
                            4.4.6.1. Others Market, 2021 - 2033 (USD Million)
                    4.5. GMP Grade
                        4.5.1. GMP Grade Market, 2021 - 2033 (USD Million)
Chapter 5. Development Phase Business Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
                    5.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
                    5.4. Pre-Clinical Therapeutics
                        5.4.1. Pre-Clinical Therapeutics Market, 2021 - 2033 (USD Million)
                    5.5. Clinical Therapeutics
                        5.5.1. Clinical Therapeutics Market, 2021 - 2033 (USD Million)
                    5.6. Marketed Therapeutics
                        5.6.1. Marketed Therapeutics Market, 2021 - 2033 (USD Million)
Chapter 6. Application Business Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
                    6.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
                    6.4. DNA Vaccines
                        6.4.1. DNA Vaccines Market, 2021 - 2033 (USD Million)
                    6.5. Cell & Gene Therapy
                        6.5.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
                    6.6. Immunotherapy
                        6.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
                    6.7. Others
                        6.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Disease Business Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. Plasmid DNA Manufacturing Market Movement Analysis
                    7.3. U.S. Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
                    7.4. Infectious Disease
                        7.4.1. Infectious Disease Market, 2021 - 2033 (USD Million)
                    7.5. Cancer
                        7.5.1. Cancer Market, 2021 - 2033 (USD Million)
                    7.6. Genetic Disorder
                        7.6.1. Genetic Disorder Market, 2021 - 2033 (USD Million)
                    7.7. Others
                        7.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Participant Categorization
                    8.2. Company Market Position Analysis, 2024
                    8.3. Participant’s Overview
                        8.3.1. Charles River Laboratories
                            8.3.1.1. Overview
                            8.3.1.2. Financial Performance
                            8.3.1.3. Product Benchmarking
                            8.3.1.4. Strategic Initiatives
                        8.3.2. Danaher (Aldevron)
                            8.3.2.1. Overview
                            8.3.2.2. Financial Performance
                            8.3.2.3. Product Benchmarking
                            8.3.2.4. Strategic Initiatives
                        8.3.3. VGXI, Inc.
                            8.3.3.1. Overview
                            8.3.3.2. Financial Performance
                            8.3.3.3. Product Benchmarking
                            8.3.3.4. Strategic Initiatives
                        8.3.4. Kaneka Corp.
                            8.3.4.1. Overview
                            8.3.4.2. Financial Performance
                            8.3.4.3. Product Benchmarking
                            8.3.4.4. Strategic Initiatives
                        8.3.5. Lonza
                            8.3.5.1. Overview
                            8.3.5.2. Financial Performance
                            8.3.5.3. Product Benchmarking
                            8.3.5.4. Strategic Initiatives
                        8.3.6. Nature Technology
                            8.3.6.1. Overview
                            8.3.6.2. Financial Performance
                            8.3.6.3. Product Benchmarking
                            8.3.6.4. Strategic Initiatives
                        8.3.7. Cell and Gene Therapy Catapult
                            8.3.7.1. Overview
                            8.3.7.2. Financial Performance
                            8.3.7.3. Product Benchmarking
                            8.3.7.4. Strategic Initiatives
                        8.3.8. Eurofins Genomics
                            8.3.8.1. Overview
                            8.3.8.2. Financial Performance
                            8.3.8.3. Product Benchmarking
                            8.3.8.4. Strategic Initiatives
                        8.3.9. Luminous BioSciences, LLC
                            8.3.9.1. Overview
                            8.3.9.2. Financial Performance
                            8.3.9.3. Product Benchmarking
                            8.3.9.4. Strategic Initiatives
                        8.3.10. Akron Biotech
                            8.3.10.1. Overview
                            8.3.10.2. Financial Performance
                            8.3.10.3. Product Benchmarking
                            8.3.10.4. Strategic Initiatives

List of Tables

Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 U.S. Plasmid DNA Manufacturing Market by Grade, 2021 - 2033 (USD Million)
Table 4 U.S. Plasmid DNA Manufacturing Market by Development Phase, 2021 - 2033 (USD Million)
Table 5 U.S. Plasmid DNA Manufacturing Market by Application, 2021 - 2033 (USD Million)
Table 6 U.S. Plasmid DNA Manufacturing Market by Disease, 2021 - 2033 (USD Million)
Table 7 Participant’s Overview

List of Figures

Fig. 1 U.S. plasmid DNA manufacturing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Market outlook
Fig. 8 Segment snapshot
Fig. 9 Competitive landscape snapshot
Fig. 10 Parent market outlook
Fig. 11 U.S. plasmid DNA manufacturing market driver analysis
Fig. 12 U.S. plasmid DNA manufacturing market restraint analysis
Fig. 13 U.S. plasmid DNA manufacturing market: Porter's analysis
Fig. 14 U.S. plasmid DNA manufacturing market: PESTEL analysis
Fig. 15 U.S. plasmid DNA manufacturing market: Grade outlook and key takeaways
Fig. 16 U.S. plasmid DNA manufacturing market: Grade movement analysis
Fig. 17 U.S. R&D grade market, 2021 - 2033 (USD Million)
Fig. 18 U.S. viral vector development market, 2021 - 2033 (USD Million)
Fig. 19 U.S. mRNA development market, 2021 - 2033 (USD Million)
Fig. 20 U.S. antibody development market, 2021 - 2033 (USD Million)
Fig. 21 U.S. DNA vaccine development market, 2021 - 2033 (USD Million)
Fig. 22 U.S. others market, 2021 - 2033 (USD Million)
Fig. 23 U.S. AAV market, 2021 - 2033 (USD Million)
Fig. 24 U.S. lentivirus market, 2021 - 2033 (USD Million)
Fig. 25 U.S. adenovirus market, 2021 - 2033 (USD Million)
Fig. 26 U.S. retrovirus market, 2021 - 2033 (USD Million)
Fig. 27 U.S. GMP grade market, 2021 - 2033 (USD Million)
Fig. 28 U.S. others market, 2021 - 2033 (USD Million)
Fig. 29 U.S. plasmid DNA manufacturing market: Development phase outlook and key takeaways
Fig. 30 U.S. plasmid DNA manufacturing market: Development phase movement analysis
Fig. 31 U.S. pre-clinical therapeutics market, 2021 - 2033 (USD Million)
Fig. 32 U.S. clinical therapeutics market, 2021 - 2033 (USD Million)
Fig. 33 U.S. marketed therapeutics market, 2021 - 2033 (USD Million)
Fig. 34 U.S. plasmid DNA manufacturing market: Application outlook and key takeaways
Fig. 35 U.S. plasmid DNA manufacturing market: Application movement analysis
Fig. 36 U.S. DNA vaccines market, 2021 - 2033 (USD Million)
Fig. 37 U.S. cell & gene therapy market, 2021 - 2033 (USD Million)
Fig. 38 U.S. immunotherapy market, 2021 - 2033 (USD Million)
Fig. 39 U.S. others market, 2021 - 2033 (USD Million)
Fig. 40 U.S. plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 41 U.S. plasmid DNA manufacturing market: Disease movement analysis
Fig. 42 U.S. infectious disease market, 2021 - 2033 (USD Million)
Fig. 43 U.S. cancer market, 2021 - 2033 (USD Million)
Fig. 44 U.S. genetic disorder market, 2021 - 2033 (USD Million)
Fig. 45 U.S. others market, 2021 - 2033 (USD Million)